Rational approach to the therapy of patients with liver cirrosis at the outcome of chronic hepatitis C

Abstract

Liver cirrhosis ranks 5th in the structure of diseases that reduce life expectancy in people of working age in Russia. The mortality rate for 1 year can reach 80% with decompensation of cirrhosis.

Objective – assessment of clinical, laboratory and instrumental data in patients with liver cirrhosis as a result of chronic hepatitis C after a course of antiviral therapy with direct antiviral drugs.

Material and methods. The study included data for the period from 2018 to 2021. Under observation were 39 patients with liver cirrhosis, pancytopenia as a result of chronic hepatitis C, who received antiviral therapy with direct antiviral drugs at the expense of compulsory medical insurance. Biochemical and virological responses were analyzed. The program included patients with different genotypes of chronic hepatitis C at the stage of compensated liver cirrhosis, Child-Pugh class A (5–6 points).

Results. After the treatment with a high degree of evidence (p<0.05), an increase in platelets was recorded, a biochemical response was obtained – a decrease in the level of aminotransferases (ALT, AST) from 4 weeks of antiviral therapy. 12 and 24 weeks after the end of therapy. Data on the reverse dynamics of the fibrotic process were obtained.

Conclusion. Direct-acting antiviral drugs have proven to be safe in patients with compensated cirrhosis, and none of them discontinued therapy due to severe adverse events.

Keywords:cirrhosis of the liver; chronic hepatitis C; direct antiviral drugs; reverse dynamics of fibrosis

Funding. The study did not have financial support.

Conflict of interest. The authors declare no conflict of interest.

Contribution. The concept and design of the study – Saranskaya Ya.E., Kiseleva L.M.; collection and processing of material – Saranskaya Ya.E.; statistical processing, text writing – Saranskaya Ya.E., Kiseleva L.M.; editing – Kiseleva L.M.

For citation: Saranskaya Ya.E., Kiseleva L.M. Rational approach to the therapy of patients with liver cirrosis at the outcome of chronic hepatitis C. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (4): 72–6. DOI: https://doi.org/10.33029/2305-3496-2022-11-4-72-76

References

1. Roth G.A., Abate D., Abate K.H., et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1736–88.

2. Kornilova E.B., Ermolaeva A.D., Rusanova M.G., Andreev D.A., Davydovskaya M.V., Ermolaeva T.N., Pokatilo A.G., et al. The strategies of drug supply for patients with chronic hepatitis C. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya [Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology]. 2017; 10 (3): 34–46. DOI: https://doi.org/10.17749/2070-4909.2017.10.3.034-046 (in Russian)

3. Nahon P., Bourcier V., Layese R., Audureau E., Cagnot C., Marcellin P., et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017; 152: 142–56.

4. Bruno S., Di Marco V., Iavarone M., Roffi L., Crosignani A., Calvaruso V., et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016; 64: 1217–23.

5. Bakulin I.G., Oganezova I.A., Skalinskaya M.I., Skazyvaeva E.V. Liver cirrhosis and complication risk management. Terapevticheskiy arkhiv [Therapeutic Archive]. 2021; 93 (8): 963–8. DOI: https://doi.org/10.26442/00403660.2021.08.200917 (in Russian)

6. Rowe I.A. Lessons from epidemiology: the burden of liver disease. Dig Dis. 2017; 35 (4): 304–9. DOI: https://doi.org/10.1159/000456580

7. Mauro E., Crespo G., Montironi C., Londono M.C., Hernandez-Gea V., Ruiz P., et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology. 2018; 67 (5): 1683–94. DOI: https://doi.org/10.1002/hep.29557

8. Pol S., Haour G., Fontaine H., Dorival C., Petrov-Sanchez V., Bourliere M., et al.; French Anrs Co22 Hepather Cohort. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017; 46 (11–12): 1054–60. DOI: https://doi.org/10.1111/apt.14352

9. Stroffolini T., Sagnelli E., Andriulli A., Colloredo G., Furlan C., Gaeta G.B., et al. Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis. PLoS One. 2017; 12 (11): e0185710. DOI: https://doi.org/10.1371/journal.pone.0185710

10. Pimpin L., Cortez-Pinto H., Negro F., et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69 (3): 718–35. DOI: https://doi.org/10.1016/j.jhep/2018.05.011

11. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5: 245–66. Epub 2020 Jan 22. DOI: https://doi.org/10.1016/S2468-1253(19)30349-8

12. Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., Volchkova E.V., Chulanov V.P. Hepatitis С and its outcomes in Russia: analysis of incidence, prevalence and mortality rates before the start of the programme of infection elimination. Infektsionnye bolezni [Infectious Diseases]. 2018; 16 (3): 37–45. DOI: https://doi.org/10.20953/1729-9225-2018-3-37-45 (in Russian)

13. Drapkina O.M., Samorodskaya I.V., Bolotova E.V., Starinskaya M.A. The nosological structure of years of potential life lost in the economically active age in the Russian Federation in 2016. Profilakticheskaya meditsina [Preventive Medicine]. 2019; 22 (1): 22–8. DOI: https://doi.org/10.17116/profmed20192201122 (in Russian)

14. Calvaruso V., Cabibbo G., Cacciola I., Petta S., Madonia S., Bellia A., et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018; 155: 411–21.

15. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020; 73 (5): 1170–218.

16. Hunyady B., Abonyi M., Gerlei Z., Gervain J., Horvath G., Jancsik V., et al. Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin (3D + RBV) treatment of hepatitis C (HCV) genotype 1 (GT1) infected patients (pts) after failure to previous first generation protease-inhibitor (PI) therapy interim analysis. J Hepatol. 2016; 64 (2): 750.

17. Aghemo A., Cologni G., Maggiolo F., Pasulo L., Rizzardini G., Magni C., et al. Safety and efficacy of directly acting antivirals in 2432 HCV patients with advanced fibrosis: an interim analysis of the Lombardia regional network for viral hepatitis. J Hepatol. 2016; 64 (2): 213.

18. Forns X., Welzel T.M., Cohen E., Jacobson I.M., Davis M., Reindollar R.,

et al. Sustained virologic response predicts fibrosis regression measured by fibrotest in HCV-infected patients. J Hepatol. 2016; 64 (2): 829–30.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»